相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Developing biomarkers to predict benefit from HGF/MET pathway inhibitors
Hartmut Koeppen et al.
JOURNAL OF PATHOLOGY (2014)
A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery
Neil R. Smith et al.
JOURNAL OF PATHOLOGY (2014)
Epistatic interactions and drug response
Britta Weigelt et al.
JOURNAL OF PATHOLOGY (2014)
The impact of germline mutations on targeted therapy
Simon A. Smith et al.
JOURNAL OF PATHOLOGY (2014)
Pathology is a necessary and informative tool in oncology clinical trials
Iris D. Nagtegaal et al.
JOURNAL OF PATHOLOGY (2014)
Implications of intratumour heterogeneity for treatment stratification
Andrew Crockford et al.
JOURNAL OF PATHOLOGY (2014)
Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity?
Jennifer Bates et al.
JOURNAL OF PATHOLOGY (2014)
Molecular pathology and prostate cancer therapeutics: from biology to bedside
Daniel Nava Rodrigues et al.
JOURNAL OF PATHOLOGY (2014)
Somatic alterations as the basis for resistance to targeted therapies
Brian G. Blair et al.
JOURNAL OF PATHOLOGY (2014)
The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Monica Arnedos et al.
JOURNAL OF PATHOLOGY (2014)
Mouse tumour models to guide drug development and identify resistance mechanisms
Meghna Das Thakur et al.
JOURNAL OF PATHOLOGY (2014)
The evolving genomic classification of lung cancer
David S. Shames et al.
JOURNAL OF PATHOLOGY (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
Jerome Galon et al.
JOURNAL OF PATHOLOGY (2014)
Using the molecular classification of glioblastoma to inform personalized treatment
Adriana Olar et al.
JOURNAL OF PATHOLOGY (2014)
New drug targets in metastatic melanoma
Blanca Homet et al.
JOURNAL OF PATHOLOGY (2014)
\Mechanisms of age-related macular degeneration and therapeutic opportunities
Menno van Lookeren Campagne et al.
JOURNAL OF PATHOLOGY (2014)
Biomarkers of drugs targeting HER-family signalling in cancer
Filippo Montemurro et al.
JOURNAL OF PATHOLOGY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Development and Use of Integral Assays in Clinical Trials
Richard L. Schilsky et al.
CLINICAL CANCER RESEARCH (2012)
Quality really matters: the need to improve specimen quality in biomedical research
Daniel Simeon-Dubach et al.
JOURNAL OF PATHOLOGY (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Foundation Medicine
Michael Eisenstein
NATURE BIOTECHNOLOGY (2012)
Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
Tatiana M. Prowell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Nikhil Wagle et al.
CANCER DISCOVERY (2012)
Cancer imaging by optical coherence tomography: preclinical progress and clinical potential
Benjamin J. Vakoc et al.
NATURE REVIEWS CANCER (2012)
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
L. V. Sequist et al.
ANNALS OF ONCOLOGY (2011)
Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase
Patricia J. T. A. Groenen et al.
HISTOPATHOLOGY (2011)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A mouse model for EML4-ALK-positive lung cancer
Manabu Soda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
